Carfilzomib is a novel proteasome inhibitor employed in the struggle against cancer. It treatment operates by interfering with the activity more info of the proteasome, a cellular structure responsible for the destruction of proteins. By hampering this mechanism, carfilzomib causes the accumulation of damaged or abnormal proteins, ultimately causin

Tepotinib, also known as {MSC2156119|the research compound|this agent), represents a significant advance in the management of non-small cell lung tumors, particularly in those harboring MET exon 14 mutations. This selective tyrosine kinase blocker|TKI shows considerable activity against cancer expansion in preclinical trials and initial patient eva

Teclistamab serves as a revolutionary novel anti-BCMA antibody drug compound, designated JNJ-64007957, holding immense potential in the therapy of multiple myeloma. This innovative agent functions by specifically binding BCMA, a marker highly expressed on the surface of myeloma cells. Through this specific mechanism, teclistamab administers a poten